Warner-Lambert zenarestat to begin Phase III for diabetic neuropathies.
Executive Summary
WARNER-LAMBERT TO BEGIN PHASE III STUDIES OF ZENARESTAT for diabetic neuropathies in the upcoming months, Parke-Davis President Pedro Cuatrecasas, MD, said during an April 11 presentation to analysts in New York City. Warner-Lambert licensed the aldose reductase inhibitor zenarestat from Fujisawa for development and marketing in territories outside Asia. The Japanese firm conducted Phase I and Phase II studies in the U.S., U.K. and Japan.